Posters

Impact of glaucoma and its treatments on the ocular surface

Poster Details

First Author: K.Belkhadir MOROCCO

Co Author(s): N. Boutimzine   S. Tachfouti   A. Amazouzi   O. Cherkaoui           

Abstract Details

Purpose:

Primary open-angle glaucoma is a common chronic condition. Its management is most often based on a hypotonic treatment instilled in eye drops. These treatments, used in the long run, have a major impact on the ocular surface, and the quality of life of the patient. This impact is modulated by the presence or absence of a preservative agent, and by the initial state of the cornea. The aim of our study was to study the impact of different hypotonizing treatments on the ocular surface, in our patients followed for primary open-angle glaucoma.

Setting:

Ophtalmology A Unit at the Ibn Sina university Hospital in Rabat, Morocco.

Methods:

We prospectively collected the data of the different patients followed for primary open-angle glaucoma. This study was conducted over a period of 6 months. All patients were known glaucomatous for at least 6 months, and used at least one hypotonizing molecule. The clinical data (OXford score, BUT) as well as the OSDI were collected

Results:

We collected 90 eyes.The mean duration of glaucoma was 26 months. Our patients were on monotherapy in 44.4% of cases, dual therapy in 36.5% , triple therapy in 14.4% and quadruple therapy in 4.7% of cases. The average BUT was 3.5 seconds, with a mean Oxford score at grade 2 in 35.5%, grade 3 in 53.3% , and grade 4 in 11.2%. The impact on quality of life, evaluated by OSDI was at 48. Comparing patients using products without preservatives, the average OSDI was 26 vs. 56 (p <0.05).The older the glaucoma, the more the OSDI was altered (p= 0,03)

Conclusions:

Glaucoma and its treatments have a major impact on the ocular surface and the quality of life of patients. The use of preservative-free treatments appears to improve the condition of the ocular surface. Nevertheless, these results seem to suggest a role for glaucomatous pathology itself in ocular surface disease independently of the treatments used.

Financial Disclosure:

None